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Abstract
Background: In Australia, higher rates of chronic hepatitis B (HBsAg) have been reported among Aboriginal and Torres
Strait Islander (Indigenous) compared with non-Indigenous people. In 2000, the Australian government implemented a
universal infant/adolescent hepatitis B vaccination program. We undertook a systematic review and meta-analysis to
assess the disparity of HBsAg prevalence between Indigenous and non-Indigenous people, particularly since 2000.
Methods: We searched Medline, Embase and public health bulletins up to March 2011. We used meta-analysis
methods to estimate HBsAg prevalence by Indigenous status and time period (before and since 2000).
Results: There were 15 HBsAg prevalence estimates (from 12 studies) among Indigenous and non-Indigenous people;
adults and pregnant women (n = 9), adolescents (n = 3), prisoners (n = 2), and infants (n = 1). Of these, only one
subgroup (adults/pregnant women) involved studies before and since 2000 and formed the basis of the meta-analysis.
Before 2000, the pooled HBsAg prevalence estimate was 6.47% (95% CI: 4.56-8.39); 16.72% (95%CI: 7.38-26.06) among
Indigenous and 0.36% (95%CI:-0.14-0.86) in non-Indigenous adults/pregnant women. Since 2000, the pooled HBsAg
prevalence was 2.25% (95% CI: 1.26-3.23); 3.96% (95%CI: 3.15-4.77) among Indigenous and 0.90% (95% CI: 0.53-1.28) in
non-Indigenous adults/pregnant women.
Conclusions: The disparity of HBsAg prevalence between Indigenous and non-Indigenous people has decreased over
time; particularly since the HBV vaccination program in 2000. However HBsAg prevalence remains four times higher
among Indigenous compared with non-Indigenous people. The findings highlight the need for opportunistic HBV
screening of Indigenous people to identify people who would benefit from vaccination or treatment.
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Background
The hepatitis B virus (HBV) is a blood borne virus which
can lead to liver failure and cancer of the liver [1]. HBV
can be transmitted through contact with infected blood
and body fluids (unsafe injecting and sexual transmis-
sion) [2], and through vertical transmission from mother
to child during birth [3]. HBV testing can provide results
for HBV surface antibodies, HBV core antibodies and
HBV surface antigen (HBsAg) [1]. Serology can determine
if a person has chronic infection, is susceptible to infection
or is immune through vaccination or past infection.
Chronic HBV infection is defined as the presence of
HBsAg for greater than six months [4]. HBsAg was first
discovered in 1965, in an Aboriginal Australian male and
was originally known as the Australia antigen [5].
The World Health Organization classifies a HBsAg
population prevalence of 8% or greater as high, 2-8% as
intermediate and 2% or less as low [6]. In Australia, an
estimated 218,000 (1.0% population prevalence) people
were living with chronic HBV in 2011 [7]. Aboriginal
and Torres Strait Islander (hereafter referred to as
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‘Indigenous’) people represent 2.6% of the Australian
population, however they account for an estimated 10%
of those living with chronic HBV [7,8]. Among Indigen-
ous Australians, a variety of modes of HBV transmission
are believed to have contributed to high levels of chronic
HBV. However it is likely that a higher proportion of in-
fections have historically occurred at birth or early in life
[9], resulting in a higher prevalence of chronic HBV in-
fection due to the increased risk of progression to
chronicity during childhood infections [10]. Australia,
has high levels of antenatal HBV screening and since the
implementation of universal infant vaccination including
a birth dose since 2000, transmission of HBV from
mother to child has decreased [11,12].
In Australia, it is estimated that nearly half of those living
with chronic HBV remain undiagnosed [7], and less than
3% are currently receiving antiviral treatment [13]. An esti-
mated 15-40% of people living with untreated chronic
HBV develop complications, including cirrhosis and/or he-
patocellular carcinoma (HCC), which is now the fastest in-
creasing cause of cancer death nationally [14,15]. The
incidence of HCC is between two and eight times greater
among Indigenous compared with non-Indigenous people
[16]. A greater burden of other diseases such as diabetes,
sexually transmitted infections and renal disease have
been reported among Indigenous compared with non-
Indigenous people and may contribute to the Indigenous
population’s vulnerability to HBV infection [17,18].
The HBV vaccine has been available in Australia since
1982 [6]. The HBV vaccine is one of the most effective
ways to prevent infection and can reduce perinatal trans-
mission by up to 90% [19]. It is also estimated that between
85-90% of HBV related deaths are vaccine-preventable
[20]. In 1985, the Northern Territory (NT), (a state with
approximately 30% of its population identifying as Indigen-
ous) introduced HBV screening to all pregnant women and
vaccination to infants born to mothers living with chronic
infection. In 1990, universal infant vaccination was im-
plemented, and in 1998 a catch-up program targeting 6-16
year olds was introduced [10]. In 2000, HBV vaccination
of all infants commenced in other states and territories of
Australia and the introduction of a universal adolescent
(teenagers aged 12-15 years) school based HBV vaccination
catch-up program commenced in 1998 [20].
In 2010, Australia’s first National Hepatitis B Strategy
2010-2013 [8] was released and recommended HBV vac-
cination among priority population groups including
people from culturally and linguistically diverse popula-
tions, children born to mothers with chronic HBV infec-
tion and Indigenous people. National guidelines released
by the National Aboriginal Community Controlled Health
Organisation (NACCHO) and the Royal Australian Col-
lege of General Practitioners recommend HBV screening
of Indigenous people who have not been vaccinated or
vaccination status is unknown as well as to people at ‘high
risk’ of blood borne viruses (BBV) [10,21].
In 1996, a HBV review provided prevalence estimates
of HBsAg in Australia and aimed to provide evidence for
the development of a HBV vaccination policy. This re-
view estimated a HBsAg prevalence among Indigenous
pregnant women of 10% [22]. Since 1996, a number of
studies have reported HBsAg prevalence among Indigen-
ous people and in 2000 Australia implemented a univer-
sal infant and adolescent HBV vaccination program. We
undertook a systematic review to assess if the disparity
in HBsAg prevalence between Indigenous and non-
Indigenous people has decreased over time, especially
since 2000. This review also provides an up-to-date pic-
ture of the burden of HBsAg among Indigenous people
and will help to inform current screening policies.
Methods
Setting
In 2011, the Australian Bureau of Statistics (ABS) esti-
mated that there were 548,370 Indigenous people (2.6% of
the Australian population) [23]. The median age of the In-
digenous population was 21 compared with 37 years in
non-Indigenous people [24]. The number of Indigenous
people varied across the states and territories of Australia
with the largest population residing in New South Wales
(152,700) followed by Queensland (144,900) [24]. The
ABS uses the Australian Standard Geographical Classifica-
tion (ASGC) to define whether a geographical area in
Australia is urban, regional or remote. This allows the
Australian government to develop different policies suit-
able to people living in regional or remote areas as they
often have less access to services such as specialist health
care [25]. A higher proportion of Indigenous compared
with non-Indigenous people live in regional and remote
areas [18]. In addition to general practice clinics in
Australia, there are an estimated 142 primary health care
centres known as Aboriginal Community Controlled
Health Services (ACCHS) which provide culturally appro-
priate medical and allied health care to Aboriginal people.
Literature search
This review was conducted according to the PRISMA
statement [26]. The electronic databases Medline and
Embase and public health bulletins were searched in
March 2011. Reference lists of studies were also exam-
ined for relevant papers.
The following MeSH search terms (and variations)
were used:
1. Hepatitis B or hepatitis B surface antigen or HBV or
HBsAg; and
2. Aboriginal or Indigenous; and
3. Australia.
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The studies were reviewed and information was extracted
by the lead author. A study was included if it presented
HBsAg prevalence among Indigenous Australians. Studies
were excluded if they reported HBsAg prevalence in
non-Indigenous people only, were reviews or com-
mentaries, or did not present primary data. For each
study that met the inclusion criteria, information was
extracted on; study period, state/territory, study design,
sex, age group, Indigenous status, sample size, HBsAg
prevalence and 95% confidence intervals (CIs) (Table 1).
The studies were separated into two time periods,
before 2000 and since 2000 when universal infant and
adolescent school based HBV vaccination programs
commenced in the majority of states and territories of
Australia. The following sub-groups were identified
across the different studies, adults, adolescents/teenagers,
pregnant women, prisoners, and infants. The authors
defined adolescents/teenagers as those aged between 9-19
years and infants as those aged 0-1 year of age. If studies
did not present 95% confident intervals (CI), the authors
calculated them using the Exact Binomial Method in
STATA 12 statistical software (STATA Corporation,
College Station TX) [27].
Meta-analysis
A meta-analysis was conducted to estimate the HBsAg
prevalence by Indigenous status and time period (before
2000 compared with since 2000). The meta-analysis fo-
cused on sub-groups with studies conducted before and
since 2000, and each study provided HBsAg prevalence es-
timates for both Indigenous and non-Indigenous people.
Only adults and pregnant women combined met this cri-
teria. The meta-analysis was conducted using weighted in-
verse variance methods, the DerSimonian-Laird method
[28] assuming a random-effects model. We used the I2 test
to estimate the approximate proportion of total variability
in point estimates that could be attributed to heterogen-
eity other than that due to chance. The results were
presented as forest plots (Figures 1 and 2).
Results
Studies
There were 22 [29-50] studies included in the review
(Figure 3), representing five states/territories of Australia
(Table 1). Of the 22 studies: nine (41%) studies were
conducted in remote areas, six (27%) in regional areas,
and seven (32%) did not specify a region in which the
study was conducted or were data analyses using patient
or midwifery databases. Ten studies were conducted be-
fore 2000 and 12 since 2000 (Table 1).
The most common study design of the 22 studies were
cross-sectional surveys conducted in schools, prisons or
a community (n = 9). Other studies were, clinical audits
conducted in community health centres (n = 7), serology
testing of a convenient sample of stored blood speci-
mens (n = 3), retrospective analyses of midwifery data-
bases (n = 2) and a longitudinal study examining sexual
health screening of pregnant women attending an
ACCHS (n = 1).
The 22 studies provided 28 HBsAg prevalence esti-
mates among Indigenous people. The studies presented
HBsAg prevalence in a number of sub-groups. A study
by Campbell and colleagues [32] presented HBsAg
prevalence by age groups and as a result we were able
to present HBsAg prevalence among Indigenous in-
fants, adolescents and adults. A study by Patterson and
colleagues [37] presented HBsAg prevalence among In-
digenous adults in two time periods, 1983-1984 and
1987-1988 and Holman and colleagues [34] presented
HBsAg prevalence among Indigenous adolescents and
adults. The 28 HBsAg estimates among Indigenous
people were in the following sub-groups; adults (n = 9),
adolescents/teenagers (n = 8), pregnant women (n = 6),
prisoners (n = 3), and infants (n = 2).
Of the 22 studies, 12 studies provided 15 HBsAg
prevalence estimates among both Indigenous and non-
Indigenous people in the following sub-groups; adults
(n = 5), pregnant women (n = 4), adolescents (n = 3),
prisoners (n = 2) and infants (n = 1).
HBsAg prevalence in individual studies before 2000
Before 2000, six of the ten studies reported a HBsAg
prevalence among Indigenous people of 8% or greater
(considered high by WHO). The highest HBsAg preva-
lence (26%) was reported by two studies; one was a cross
sectional survey by Burrell and colleagues in 1979-82 of
stored blood samples [31] and the other an investigation
of a cluster of HBsAg seropositive cases in northern
Queensland among Indigenous adolescents [39]. There
were six studies in adults and pregnant women; three
were community-based surveys, and three serology test-
ing of a convenient sample of stored blood specimens.
Six of the ten studies presented HBsAg prevalence for
both Indigenous and non-Indigenous people and the
prevalence estimates were higher among Indigenous
compared with non-Indigenous adults, pregnant women
and adolescents. The greatest disparity was in the study
by Burrell and colleagues [31] which found HBsAg
prevalence among Indigenous adults of 26% compared
with 0.2% in non-Indigenous adults. Two studies [32,38]
(conducted in 1985 and 1989) presented breakdowns by
sex, and found the HBsAg prevalence among Indigenous
adults and infants, was higher in males compared with
females. A study by Gardner and colleagues [38] in the
NT (conducted in 1989), found an overall HBsAg preva-
lence among Indigenous adolescents aged 9-17 years of
8.2%, however the prevalence was higher among Indi-
genous children living in remote compared with urban
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Pre Adolescents Barrett [29], 1972 1972 QLD & NT Cross sectional survey of blood samples M,F N/S Indigenous 731 3.41 2.23-5.01**
Pre Adults Barrett [29], 1972 1972 QLD & NT Cross sectional survey of blood samples M,F N/S Indigenous 160 8.13 4.40-13.49**
Pre Adults Barrett [30], 1976 1976 QLD & NT Cross sectional survey of blood samples M,F N/S Indigenous 662 6.90 5.13-9.16**
Non-Indigenous 234 0.38 0.01-2.36**
Pre Adults Burrell [31], 1983 1979-1982 SA Cross sectional survey of blood samples M,F N/S Indigenous 327 25.99 21.32-31.10*
Non-Indigenous 22,800 0.20 0.15-0.30**
Pre Adolescents Campbell [32], 1985 November 1985 NSW Cross sectional Community survey M,F 12-16 Indigenous 89 12.02 6.33-21.04*
Pre Pregnant women Moore [33], 1987 1983-1985 WA Cross sectional Midwifery analyses F N/S Indigenous 817 3.60 2.39-7.88**
Pre Adults Holman [34], 1987 May-Sept 1986 WA Cross sectional Community survey M,F N/S Indigenous 1,150 7.90 6.42-9.63**
Pre Adolescents Holman [34], 1987 May-Sept 1986 WA Cross sectional Community survey M,F 12-19 Indigenous 177 4.52 1.97-8.71**
Pre Adults Campbell [36], 1989 Nov 1985 NSW Cross sectional Community survey M,F N/S Indigenous 375 19.20 15.34-23.56**
Non-Indigenous 268 2.01 0.61-4.30
Pre Adolescents Gill [35], 1990 1989 WA Cross sectional School survey M,F 10-19 Indigenous 186 6.1 3.8-9.5**
Non-Indigenous 301 0.3 0.1-1.8**
Pre Adolescents Campbell [36], 1989 1992 NSW Cross sectional Community survey M,F 12-16 Indigenous 297 14.01 10.39-18.63
Non-Indigenous 111 0.0 0.0-0.0
Pre Adults Patterson [37], 1993 1983-1984 NSW Cross sectional Community survey M,F N/S Indigenous 236 16.91 12.39-22.36**
Non-Indigenous 268 2.01 0.61-4.30**
Pre Adults Patterson [37], 1993 1987-1988 NSW Cross sectional Community survey M,F N/S Indigenous 212 5.19 2.62-9.09**
Non-Indigenous 422 0 0.0-0.0**
Pre Infants Campbell [32], 1989 1992 NSW Cross sectional Community survey M,F 0-1 Indigenous 49 22.45 3.89-31.66**
Non-Indigenous 11 9.09
Pre Adolescents Gardner [38], 1992 1992 NT Cross sectional school survey M,F 9-13 Indigenous 439 8.20 5.81-11.17**
Non-Indigenous 665 0.41 0.09-1.31**
Pre Adolescents Malcolm [39], 2000 1999 QLD Cross sectional Community survey M,F N/S Indigenous 108 26.02 17.97-35.25**
Post Pregnant women Panaretto [40], 2006 2000-2003 QLD Longitudinal cohort F 15-40 Indigenous 419 0.81 0.15-2.08
Post Pregnant women Wood [41], 2008 2002-2004 NT Cross sectional Midwifery analyses F 10-50 Indigenous 522 5.50 3.75-7.88
Non-Indigenous 516 0.79 0.21-1.97
Post Pregnant women Romanes [42], 2006 2003 NT Cross sectional clinical audit F 15-47 Indigenous 540 4.09 2.57-6.10
15-47 Non-Indigenous 862 1.19 0.56-2.12
Post Pregnant women Schultz [43], 2007 2005 NT Cross sectional clinical audit F N/S Indigenous 432 3.21 1.78-5.37




















Table 1 HBsAg prevalence estimates among indigenous and non-indigenous Australians by study population and before and since 2000 (Continued)
Post Pregnant women Schultz [44], 2008 2003 & 2005 NT Cross sectional data analysis F 15+ Indigenous 973 3.70 2.60-5.09**
N/S Non-Indigenous 1221 0.90 0.45-1.61
Post Prisoners van der Poorten [45], 2008 2002-2005 NSW Cross sectional prison survey M 12-19 Indigenous 179 3.41 1.30-7.15**
Non-Indigenous 530 1.09 0.42-2.45**
Post Prisoners Templeton [46], 2010 2000-2004 NSW Cross sectional audit M 14-20 Indigenous 79 11.39 6.29-19.85
Post Prisoners Gilles [47], 2008 2006 WA Cross sectional clinical audit M,F 18-50 Indigenous 155 3.24 1.06-7.37
18-50 Non-Indigenous 30 3.33 0.08-17.22
Post Adults Carroll [48], 2010 2008 QLD Cross sectional clinical audit M,F 15-54 Indigenous 112 0.93 0.02-4.87
Post Adults Carroll [49], 2010 2008 NT Cross sectional clinical audit M,F 15-54 Indigenous 112 11.96 6.33-19.03
Post Adolescents Dent [50], 2005 May-July 2005 NT Cross sectional Community survey M,F 14-15 Indigenous 37 11.08 3.03-25.42




















areas. Nine of the ten studies conducted before 2000,
were actually conducted before 1990.
HBsAg prevalence in individual studies since 2000
Since 2000, nine of twelve studies reported HBsAg
prevalence among Indigenous people between 2-8%
(considered intermediate by WHO); the highest estimate
was 12% from a study in 2008 which was a clinical audit
of adults conducted in a remote ACCHS in the NT.
Three other studies in the NT aimed to provide more
population-based estimates. The first by Schultz and
colleagues [44] estimated antenatal population-based
HBsAg prevalence in the NT by reviewing over 2000 re-
cords from two hospitals (in Darwin and Alice Springs).
These two hospitals were responsible for delivering 71%
of Indigenous births in 2003 and 2005 and found the
HBsAg prevalence among Indigenous pregnant women
was 4%. The second study by Wood and colleagues [41]
involved data linkage of the NT Midwives database and
HBV serology data and found the HBsAg prevalence was
5.5% among Indigenous pregnant women. The study by
Wood and colleagues reported the HBsAg prevalence
among pregnant women by age groups and found the
prevalence was lowest in 15-19 year olds, and highest in
35-39 year olds. The third study by Romanes and col-
leagues [42] in 2003 involved a clinical audit of medical
records at the Royal Darwin Hospital and found the
HBsAg prevalence among Indigenous pregnant women
was 4.1%. There was one further study in pregnant women
[40], conducted at an ACCHS in Northern Queensland
between 2000-2003. The study was an intervention pro-
gram aimed at improving sexual health screening during
pregnancy, and found a low HBsAg prevalence of 0.8%.
Three of the studies in pregnant women reported very
high HBsAg screening rates (greater than 90%).
Three further studies involved clinical audits, with two
of the three [45,47] comparing HBsAg prevalence among
Indigenous and non-Indigenous prisoners. These two
studies in prisoners had small samples sizes (101 and 185),
and were conducted mostly in males (>80%), with one
study showing a higher HBsAg prevalence among Indigen-
ous (3%) compared with non-Indigenous prisoners (1%)
and the other found a similar prevalence of 3% among In-
digenous and non-Indigenous prisoners. The third study
focused on adolescents (n = 37) attending a remote health
service and found a HBsAg prevalence of 11%. There were
no HBsAg prevalence studies since 2000 among infants.
Since 2000, there were six studies which presented a
HBsAg prevalence for both Indigenous and non-
Indigenous people with five estimating a higher HBsAg
prevalence among Indigenous compared with non-
Indigenous people.
NOTE: Weights are from random effects analysis
.
.






Subtotal  (I-squared = 63.4%, p = 0.042)
Campbell, 1989







































, Study period HBsAg prevalence estimate
0
Figure 1 HBsAg prevalence before 2000, by author, study period among Indigenous compared with non-Indigenous adults.
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92 duplicates removed 
40 studies assessed for  
eligibility
22 studies were included 
132 studies identified
18 studies were excluded
because they did not 
provide HBsAg estimates 
among Indigenous 
Australians
10 before 2000 and
12 since 2000
9 cross sectional 
surveys in schools, 
prisons or a 
community 
7 clinical audits 
in community 
health centres in 
remote areas












Figure 3 Flow diagram of studies included in the review.
NOTE: Weights are from random effects analysis
.
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Figure 2 HBsAg prevalence since 2000, by author, study period among Indigenous compared with non-Indigenous pregnant women.
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Meta-analysis
Before 2000, the pooled HBsAg prevalence estimate was
6.47% (95%CI:4.56-8.39; I2 = 97.2%, p < 0.001, 3 studies);
16.72% (95%CI:7.38-26.06; I2 = 94.9%, p < 0.001) among
Indigenous compared with 0.36% (95%CI:-0.14-0.86; I2 =
63.4%, p = 0.042) in non-Indigenous adults/pregnant
women (Figure 1).
Since 2000, the pooled HBsAg prevalence estimate was
2.25%, (95%CI: 1.26-3.23; I2 = 85.6%, p < 0.001) (4 stu-
dies); 3.96% (95%CI:3.15-4.77 I2 = 0%, p = 0.393) among
Indigenous compared with 0.90% (95%CI:0.53-1.28; I2 =
0%, p = 0.810) in non-Indigenous adults/pregnant women
(Figure 2).
Discussion
The disparity in HBsAg prevalence between Indigenous
and non-Indigenous Australians appears to have de-
creased over time, especially in studies conducted since
2000 compared with before 2000. This coincides with the
introduction of universal vaccination programs in
Australia, for adolescents (since 1998) and infants (since
2000). However in studies conducted since 2000, the
prevalence of chronic HBV remains four times higher
among Indigenous compared with non-Indigenous people.
This review found a higher HBsAg prevalence among
Indigenous pregnant women compared with non-
Indigenous pregnant women in studies conducted since
2000 (mainly in the NT) and the study by Wood and
colleagues [41] found HBsAg prevalence was slightly
lower in 15-19 year olds pregnant women, an age group
more likely to have been vaccinated. These findings
highlight the need for ongoing antenatal screening of
pregnant women living in remote Indigenous communi-
ties and vaccination to not only decrease chronic HBV
prevalence among pregnant women but also perinatal
transmission from mother to child [19].
The higher HBsAg prevalence found among Indigenous
compared with non-Indigenous adults highlights the im-
portance of offering opportunistic HBV screening to Indi-
genous people. In 1990, New Zealand (NZ) introduced a
HBV screening program in response to the higher HBV
prevalence in Maori, Pacific Islander and Asian popula-
tions compared with other New Zealanders [51]. The
program was based primarily on supporting general prac-
titioners (GPs) and Maori and Pacific Islander providers to
recruit individuals for opportunistic HBV testing, by invi-
tation letter or phone call, or through community promo-
tion, community meetings or churches. In a three-year
period between 1999 and 2002 a total of 177,328 people
were tested for HBV; 153,605 (87%) were Maori, Pacific
Islander or Asian adults, and the program reached 28%,
35% and 20% of the Maori, Pacific Islander and Asian
adult target population, respectively. In Australia, general
practitioners and ACCHS are ideally placed to undertake
opportunistic HBV screening, as studies have shown that
the majority of Indigenous people attended ACCHS for
their health care and health education needs [52].
HBV screening also identifies those in need of vaccin-
ation, treatment and management. Appropriate treatment
of chronic HBV has been found to substantially reduce
the risk of liver cancer [53] and is cost effective in the
Australian context [54]. Systematic liver cancer surveil-
lance in NZ has shown to increase the survival of people
enrolled in the HBV screening programme [55,56].
There are some limitations to be considered when
interpreting our findings. Many of the studies were clin-
ical audits conducted in community health centres or
ACCHS and thus the findings could be influenced by
the screening protocols in these health services. This
could potentially over-estimate HBsAg prevalence if cli-
nicians are preferentially testing those with symptoms or
at higher risk of infection rather than conducting univer-
sal screening. That being said, in a number of studies
among pregnant women the testing uptake was consist-
ently over 90%. Furthermore, many of the studies were
conducted in regional or remote areas, so results may
not be generalisable to Indigenous people living in urban
areas of Australia. With respect to included studies, we
did not search all the grey literature so it is possible that
some studies were not identified. In addition, although
the comparison of HBsAg prevalence before and since
2000 via meta-analysis was undertaken, the findings may
be influenced by different study designs and populations
included in these periods. Finally, we were unable to
conduct a meta-analysis for a number of sub-groups due
to the limited number of studies available.
Conclusion
Although HBsAg prevalence appears to have decreased
over time in Australia, it remains four times higher among
Indigenous compared with non-Indigenous people. Our
findings suggest the need for opportunistic HBV screening
of Indigenous people to identify those who need vaccin-
ation and those needing treatment and regular monitoring.
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